TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6219156
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol plus oral oxtriphylline
Study: 6219156
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium and fenoterol plus oral oxtriphylline
Study: 26637166
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2 mg) administered as 3 monthly loading doses, followed by injections every 2 months over 12 months
Study: 24388619
Drug: Chlorthalidone-based stepped-care
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone-based stepped-care therapy
Study: 23017669
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (three cycles of OxMdG: oxaliplatin 85 mg/m², l‐folinic acid 175 mg, fluorouracil 400 mg/m² bolus, then 2400 mg/m² by 46 h infusion) followed by surgery and a further nine cycles of OxMdG
Study: 23017669
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (12 cycles of OxMdG)
Study: 15288712
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (human regular insulin 4 x 40 IU/d)
Study: 9310280
Drug: Almokalant at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almokalant at 100 nmol/l
Study: 9310280
Drug: Almokalant at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almokalant at 50 nmol/l
Study: 9310280
Drug: Almokalant at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almokalant at 20 nmol/l
Study: 9310280
Drug: Almokalant at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almokalant at 150 nmol/l
Study: 28937221
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg tablet) under fasting conditions
Study: 28937221
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg tablet) under fed conditions
Study: 28937221
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg tablet)
Study: 25982133
Drug: Subanaesthetic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subanaesthetic ketamine (0.29 mg kg(‐1) h(‐1) for 1 h, followed by 0.57 mg kg(‐1) h(‐1) for another hour)
Study: 23813743
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 4-aminopyridine (4-AP) four times a day for 3 days
Study: 23813743
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 4-aminopyridine (4-AP) four times a day for 4 days
Study: 21541781
Drug: Macitentan 600
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 600 mg
Study: 21541781
Drug: Macitentan 300
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 300 mg
Study: 17400413
Drug: computer-based hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: computer-based hormone therapy decision-aid
Study: 10419902
Drug: Functional drug
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional drug efflux (assessed using Di(OC)(2) and Rhodamine 123)
Study: 7587453
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training consisting of 1 h of group walking twice daily, with intensity stratified into four levels based on initial exercise capacity.
Study: 2276014
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative combination chemotherapy (5‐fluorouracil, lomustine (CCNU) and vincristine)
Study: 2276014
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative combination chemotherapy
Study: 6157615
Drug: Synchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronization therapy (control group)
Study: 6157615
Drug: Synchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronization therapy (for advanced non-Hodgkin lymphomas)
Study: 31641913
Drug: QL2 regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL2 regional anesthesia with 150 mg of ropivacaine combined with standard analgesia
Study: 21719865
Drug: Injectable poly-L-lactic
Normalized name: L-Lactic acid
DrugBank: L-Lactic acid (DB14475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable poly-L-lactic acid (PLLA)
Study: 31469923
Drug: Injectable poly-D,L-lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable poly-D,L-lactic acid (PDLLA)
Study: 27403887
Drug: EMLA® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® cream (anaesthetic cream), n = 34, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Study: 27403887
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, n = 36, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Study: 25271011
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 3 (250,000 IU, single dose in November)
Study: 17202008
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mL, 40 mg, 2%)
Study: 17202008
Drug: Diphenhydramine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (2 mL, 20 mg)
Study: 17202008
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL normal saline)
Study: 1480917
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg nightly (increased to 40 mg if cholesterol > 200 mg/dl after 6 weeks)
Study: 1480917
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily (dose kept constant)
Study: 6500445
Drug: Split tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split tetanus vaccine
Study: 6500445
Drug: Normal adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal adsorbed toxoid vaccine
Study: 2944434
Drug: Ketanserin by
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin by continuous infusion
Study: 2944434
Drug: Placebo (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equal infusion rate)
Study: 27020698
Drug: Gel of
Normalized name: ZINC OXIDE 160 mg in 1 g TOPICAL OINTMENT [Angel of mine Diaper Rash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel of chamomile
Study: 27020698
Drug: Cream of
Normalized name: Nubasics Soup Cream of Chicken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream of urea
Study: 23201763
Drug: Beta-alanine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (4 weeks loading phase of 4.8 g/day and 3.2 g/day thereafter)
Study: 15998756
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake; specific dosage and duration not mentioned.
Study: 12757058
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and/or tolerability)
Study: 1478168
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice daily for one year)
Study: 24768247
Drug: Dose-reduction-by-half group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduction-by-half group
Study: 24768247
Drug: Dose maintenance
Normalized name: XCOPRI 250mg Daily Dose Maintenance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose maintenance group
Study: 20819899
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (0.5 mg/kg per day)
Study: 20819899
Drug: Other glucocorticoid
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other glucocorticoid doses and preparations
Study: 11081531
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisolone daily for 2 weeks
Study: 9002329
Drug: Tetravalent rhesus‐human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent rhesus‐human reassortant rotavirus vaccine (4 x 10(4) plaque‐forming units/dose)
Study: 7039017
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral doses of prednisone
Study: 22337714
Drug: FCR (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCR (fludarabine and cyclophosphamide in combination with rituximab)
Study: 22337714
Drug: FCCam (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCCam (fludarabine and cyclophosphamide in combination with alemtuzumab)
Study: 18503008
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral mixed meal
Study: 18503008
Drug: Intraperitoneal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal glucose infusion
Study: 15816811
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment at a dosage of 1.6 IU/day (0.53 mg/day) for 6 months followed by 12 months of active GH treatment
Study: 15816811
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up after cessation of GH treatment
Study: 227618
Drug: 4-month exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month exercise program (3-4 weekly sessions)
Study: 27521821
Drug: Pycnogenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (50 mg orally, 3 times daily)
Study: 27521821
Drug: Diosmin/Hesperidin (450/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin/Hesperidin (450/50 mg orally, twice daily)
Study: 23296063
Drug: Paclitaxel/platinum chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/platinum chemotherapy followed by liposomal doxorubicin and gemcitabine (Group B)
Study: 23296063
Drug: Paclitaxel/platinum chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/platinum chemotherapy followed by platinum compounds, docetaxel and oral etoposide (Group A)
Study: 23296063
Drug: Post-relapse treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-relapse treatment in Group B
Study: 23296063
Drug: Post-relapse treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-relapse treatment in Group A
Study: 21970950
Drug: Bevacizumab (PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (PRN dosing regimen)
Study: 21970950
Drug: Bevacizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (monthly treatment)
Study: 21970950
Drug: Ranibizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (monthly treatment)
Study: 18328464
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBTgsh)
Study: 18328464
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBTgsh) and Behavioral weight loss (BWLgsh)
Study: 16864762
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 10-session, manualized, individually administered regimen added to psychiatric consultation intervention
Study: 12638392
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) single doses (0.25, 0.5, or 1 mg) on cycle day 3
Study: 12638392
Drug: Cetrorelix (CET)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix (CET) multiple doses from cycle day 3 to day 16
Study: 9060527
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) and racemic leucovorin (d,l‐LV)
Study: 9060527
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) combined with the pure l-isomer of leucovorin (l‐LV)
Study: 8181576
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low-dose recombinant interleukin-2 via central venous access (CVA)
Study: 8181576
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics via the CVA
Study: 8181576
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of low dose streptokinase via the CVA
Study: 2535983
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (1500 aPTT-U/24 h)
Study: 2535983
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (3 x 5000 IU/24 h)
Study: 9194109
Drug: Bio-Hep-B (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Hep-B (2.5 micrograms/dose)
Study: 9194109
Drug: Engerix-B (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (10 micrograms/dose)
Study: 3912647
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of arginine pyroglutamate three times a day
Study: 30535959
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate tablet (test product)
Study: 30535959
Drug: ZYTIGA® (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYTIGA® (250 mg, reference product)
Study: 21059213
Drug: MPH1 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH1 (7.5 mg Isoleucine‐Proline‐Proline)
Study: 21059213
Drug: MPH2 (6.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH2 (6.6 mg Methionine‐Alanine‐Proline, 2.3 mg Leucine‐Proline‐Proline, 1.8 mg IPP)
Study: 15857459
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel applied twice daily for 4 weeks
Study: 7740405
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy for high-grade soft-tissue sarcomas
Study: 7740405
Drug: Neoadjuvant induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant induction chemotherapy, regional perfusion with cytostatics (± hyperthermia), externally applicated deep regional tumor hyperthermia with systemic chemotherapy
Study: 7740405
Drug: Uncontrolled adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled adjuvant treatment of soft-tissue sarcomas with cytostatic drugs
Study: 2179591
Drug: Abdominal injection
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal injection of insulin for 3 days
Study: 2179591
Drug: Rotating injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotating injection among arms, abdomen, and thighs for 3 days
Study: 6102456
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg d-amphetamine administered intravenously
Study: 27821644
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg + allopurinol
Study: 27821644
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg + allopurinol
Study: 21174586
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C and 400 IU natural vitamin E (RRR α tocopherol) daily from the second trimester until delivery
Study: 11578890
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg with 4% lidocaine (Group I; n = 15)
Study: 11578890
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL with saline (Group 2; n = 16)
Study: 25277645
Drug: Amoxicillin/clavulanate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate and metronidazole (2-antimicrobial group)
Study: 25277645
Drug: Amoxicillin/clavulanate (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (control group)
Study: 25277645
Drug: Both antibiotics
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antibiotics continued (2-antimicrobial group)
Study: 20061435
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (50 mg/d)
Study: 9641566
Drug: Local nasal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nasal immunotherapy (LNIT)
Study: 10812221
Drug: Priorix (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priorix (new MMR vaccine)
Study: 10812221
Drug: Triviraten (widely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triviraten (widely used MMR vaccine)
Study: 30948273
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg once daily continuously
Study: 30241559
Drug: Pre-prepared PHEA
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-prepared PHEA equipment and drugs
Study: 24481640
Drug: i-CEOP (intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-CEOP (intensive chemotherapy): cyclophosphamide 1,500 mg, epirubicin 150 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Study: 24481640
Drug: i-CEOP (intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-CEOP (intensive chemotherapy)
Study: 24481640
Drug: s-CEOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-CEOP (standard chemotherapy): cyclophosphamide 750 mg, epirubicin 75 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Study: 24481640
Drug: s-CEOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-CEOP (standard chemotherapy)
Study: 22205319
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy)
Study: 22205319
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.9 g/d, 0.3% of daily energy)
Study: 22205319
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI ≥25
Study: 22205319
Drug: Moderately high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI <25
Study: 17726919
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)
Study: 12197367
Drug: CEE-MPA (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE-MPA (conjugated equine oestrogens 0.625 mg + medroxyprogesterone acetate 5 mg)
Study: 7781462
Drug: 200 mg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg/hr L-arginine
Study: 7781462
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg erythromycin
Study: 2180492
Drug: Chlorambucil at
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil at a daily dose of 0.1 mg/kg
Study: 2180492
Drug: Stage A
Normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage A patients with hemoglobin ≥ 120 g/L and lymphocyte count < 30 x 10(9)/L
Study: 31200160
Drug: Real indoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real indoor air purification (PM2.5 exposure reduced to 28.3 μg/m3)
Study: 31200160
Drug: Sham indoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham indoor air purification (PM2.5 exposure at 56.9 μg/m3)
Study: 21509668
Drug: Hongyou Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hongyou Ointment and Shengji Powder (CM group)
Study: 21509668
Drug: Mupirocin ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin ointment, growth factor (bFGF), and Vaseline gauze (WM group)
Study: 21509668
Drug: CM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM treatment
Study: 11112243
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg (two 500-mg Extra Strength Tylenol tablets)
Study: 9167744
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AT II) infusion
Study: 9167744
Drug: Baseline (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (without AT II infusion)
Study: 8460050
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg p.o. HS on postoperative days 1, 2, and 3
Study: 3079935
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day leuprolide acetate
Study: 3079935
Drug: 3 mg/day
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/day diethylstilbestrol (DES)
Study: 28695457
Drug: Islet cell
Normalized name: Islet cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet cell antibody testing
Study: 18685503
Drug: Symbiotic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic formulation (Flortec)
Study: 18685503
Drug: Symbiotic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic formulation (Flortec) in IBS-predominant diarrhea
Study: 16549835
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/d for 6 weeks, then 10 mg/d for 18 weeks